Charles Schwab Investment Management Inc. Purchases 38,944 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Charles Schwab Investment Management Inc. boosted its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 16.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 273,135 shares of the company's stock after purchasing an additional 38,944 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.52% of Janux Therapeutics worth $14,624,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of JANX. FMR LLC lifted its stake in shares of Janux Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company's stock worth $355,475,000 after buying an additional 47,075 shares during the last quarter. Janus Henderson Group PLC lifted its position in Janux Therapeutics by 40.0% during the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company's stock worth $114,587,000 after acquiring an additional 721,563 shares during the last quarter. Geode Capital Management LLC lifted its position in Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company's stock worth $30,107,000 after acquiring an additional 38,490 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of Janux Therapeutics by 190.2% during the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company's stock worth $17,985,000 after acquiring an additional 259,445 shares during the period. Finally, Barclays PLC grew its position in shares of Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company's stock valued at $7,907,000 after purchasing an additional 144,883 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Janux Therapeutics Stock Up 6.0 %

Shares of NASDAQ:JANX traded up $1.80 during trading on Monday, hitting $31.74. 709,129 shares of the company were exchanged, compared to its average volume of 825,929. Janux Therapeutics, Inc. has a 1-year low of $28.92 and a 1-year high of $71.71. The company has a market capitalization of $1.88 billion, a P/E ratio of -27.13 and a beta of 3.23. The business's 50 day moving average is $36.89 and its 200-day moving average is $46.46.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Stifel Nicolaus upped their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the company a "buy" rating in a report on Tuesday, December 3rd. Lifesci Capital raised shares of Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $200.00 price target on shares of Janux Therapeutics in a research report on Wednesday, December 11th. BTIG Research raised their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, December 3rd. Finally, Wedbush reaffirmed an "outperform" rating and set a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $92.44.

Insider Activity at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. bought 110,206 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the transaction, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This trade represents a 1.10 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total value of $1,404,750.00. Following the transaction, the chief executive officer now directly owns 217,054 shares in the company, valued at $12,196,264.26. The trade was a 10.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,002 shares of company stock worth $2,684,703 in the last quarter. 29.40% of the stock is owned by insiders.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.